YU65096A - Nova kristalna modifikacija cdch, postupak za njeno pripremanje i farmaceutski preparati koji je sadrže - Google Patents

Nova kristalna modifikacija cdch, postupak za njeno pripremanje i farmaceutski preparati koji je sadrže

Info

Publication number
YU65096A
YU65096A YU65096A YU65096A YU65096A YU 65096 A YU65096 A YU 65096A YU 65096 A YU65096 A YU 65096A YU 65096 A YU65096 A YU 65096A YU 65096 A YU65096 A YU 65096A
Authority
YU
Yugoslavia
Prior art keywords
preparation
pharmaceutical preparations
preparations containing
cddh
crystal modification
Prior art date
Application number
YU65096A
Other languages
English (en)
Other versions
YU49485B (sh
Inventor
Alfons Dr. Grunenberg
Patrick Dr. Bosche
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU65096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of YU65096A publication Critical patent/YU65096A/sh
Publication of YU49485B publication Critical patent/YU49485B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na novi monohidrat 1-ciklopropil-7-(/S,S/-2,8-diazabiciklo /4.3.0/non-8-il)6-fluor-1,4-dihidro-8-metoksi-4-okso-3-hinolin-karbonske kiseline hidrohlorid (CDCH), na postupak za njegovo pripremanje i na farmaceutske preparate koji ovaj monohidrat sadrže kao delotvornu supstancu.
YU65096A 1995-12-12 1996-12-06 Nova kristalna modifikacija cdch, postupak za njeno pripremanje i farmaceutski preparati koji je sadrže YU49485B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (2)

Publication Number Publication Date
YU65096A true YU65096A (sh) 1998-12-23
YU49485B YU49485B (sh) 2006-08-17

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
YU65096A YU49485B (sh) 1995-12-12 1996-12-06 Nova kristalna modifikacija cdch, postupak za njeno pripremanje i farmaceutski preparati koji je sadrže

Country Status (42)

Country Link
US (1) US5849752A (sh)
EP (1) EP0780390B1 (sh)
JP (1) JP4104687B2 (sh)
KR (1) KR100525146B1 (sh)
CN (1) CN1061348C (sh)
AR (1) AR005009A1 (sh)
AT (1) ATE221531T1 (sh)
AU (1) AU708006B2 (sh)
BG (1) BG62258B1 (sh)
BR (1) BR9605968A (sh)
CA (1) CA2192418C (sh)
CO (1) CO4480105A1 (sh)
CU (1) CU22774A3 (sh)
CZ (1) CZ288657B6 (sh)
DE (2) DE19546249A1 (sh)
DK (1) DK0780390T3 (sh)
EE (1) EE03474B1 (sh)
ES (1) ES2179910T3 (sh)
HR (1) HRP960558B1 (sh)
HU (1) HU226521B1 (sh)
ID (1) ID22625A (sh)
IL (1) IL119795A (sh)
IN (1) IN185805B (sh)
MA (1) MA24342A1 (sh)
MY (1) MY117492A (sh)
NL (1) NL300109I1 (sh)
NO (1) NO306725B1 (sh)
NZ (1) NZ299905A (sh)
PL (1) PL184885B1 (sh)
PT (1) PT780390E (sh)
RO (1) RO119782B1 (sh)
RU (1) RU2162468C2 (sh)
SA (1) SA96170492B1 (sh)
SG (1) SG47201A1 (sh)
SI (1) SI0780390T1 (sh)
SK (1) SK282805B6 (sh)
SV (1) SV1996000109A (sh)
TR (1) TR199600970A2 (sh)
TW (1) TW411340B (sh)
UA (1) UA35638C2 (sh)
YU (1) YU49485B (sh)
ZA (1) ZA9610405B (sh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220547T1 (de) * 1997-09-25 2002-08-15 Bayer Ag Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
TR200101310T2 (tr) * 1998-11-10 2001-10-22 Bayer Aktiengesellschaft Farmasötik moksifloksasin preparatı.
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
US20060252789A1 (en) * 2002-10-31 2006-11-09 Sujay Biswas Amorphous moxifloxacin hydrochloride
EP2113505A1 (en) 2003-04-09 2009-11-04 Dr. Reddy's Laboratories, Ltd. A crystalline form III of anhydrous moxifloxacin hydrochloride and processes for the preparation thereof
US20060264635A1 (en) * 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
DE602004018370D1 (de) * 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
SI2032521T1 (sl) 2006-06-27 2010-02-26 Sandoz Ag Nov postopek za pripravo soli
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
NZ576929A (en) * 2006-11-13 2012-07-27 Cipla Ltd Crystalline anhydrous form C of moxifloxacin hydrochloride
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
EP2349220B1 (en) * 2008-10-09 2012-07-25 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
EP2342204A1 (en) * 2008-11-06 2011-07-13 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EA028676B1 (ru) 2008-12-08 2017-12-29 Рациофарм Гмбх Спрессованный моксифлоксацин
CN102459169B (zh) 2009-05-15 2014-12-31 莱德克斯制药有限公司 氧化还原药物衍生物
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
US9388178B2 (en) 2012-12-04 2016-07-12 Mankind Research Centre Process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
BR112015023044A8 (pt) 2013-03-15 2021-09-28 Melinta Subsidiary Corp Métodos para tratar infecções em pacientes acima do peso e obesos com o uso de antibióticos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
AU618235B2 (en) * 1986-03-31 1991-12-19 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives, their preparation and use
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
TW209865B (sh) 1992-01-10 1993-07-21 Bayer Ag
WO1993015070A1 (en) * 1992-01-31 1993-08-05 Chugai Seiyaku Kabushiki Kaisha Crystal of quinolonecarboxylic acid derivative hydrate
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
NO301165B1 (no) * 1992-12-25 1997-09-22 Daiichi Seiyaku Co Bicykliske aminderivater og antibakterielle midler inneholdende disse
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
ATE170400T1 (de) * 1994-04-07 1998-09-15 Pfizer Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen

Also Published As

Publication number Publication date
PL317415A1 (en) 1997-06-23
US5849752A (en) 1998-12-15
IL119795A (en) 1998-12-27
TW411340B (en) 2000-11-11
AU708006B2 (en) 1999-07-29
SK159196A3 (en) 1997-10-08
ES2179910T3 (es) 2003-02-01
CN1061348C (zh) 2001-01-31
MA24342A1 (fr) 1998-07-01
NZ299905A (en) 1998-09-24
BG101043A (en) 1998-04-30
CA2192418C (en) 2001-06-12
HU9603428D0 (en) 1997-01-28
TR199600970A2 (tr) 1997-06-21
PL184885B1 (pl) 2003-01-31
MX9606325A (es) 1997-10-31
HUP9603428A2 (en) 1997-08-28
RU2162468C2 (ru) 2001-01-27
SG47201A1 (en) 1998-03-20
SI0780390T1 (en) 2002-10-31
ATE221531T1 (de) 2002-08-15
SA96170492B1 (ar) 2006-05-23
CA2192418A1 (en) 1997-06-13
ID22625A (id) 1999-12-02
RO119782B1 (ro) 2005-03-30
NO965298D0 (no) 1996-12-11
NO306725B1 (no) 1999-12-13
AR005009A1 (es) 1999-04-07
JPH09169757A (ja) 1997-06-30
EP0780390A1 (de) 1997-06-25
IL119795A0 (en) 1997-03-18
HU226521B1 (en) 2009-03-30
PT780390E (pt) 2002-11-29
NL300109I1 (nl) 2003-02-03
SK282805B6 (sk) 2002-12-03
DE59609501D1 (de) 2002-09-05
EE9600201A (et) 1997-06-16
YU49485B (sh) 2006-08-17
KR100525146B1 (ko) 2006-01-27
NO965298L (no) 1997-06-13
DE19546249A1 (de) 1997-06-19
CN1160052A (zh) 1997-09-24
IN185805B (sh) 2001-05-05
UA35638C2 (uk) 2001-04-16
CO4480105A1 (es) 1997-07-09
MY117492A (en) 2004-07-31
HRP960558A2 (en) 1998-02-28
HUP9603428A3 (en) 1997-10-28
CZ364696A3 (en) 1997-07-16
HRP960558B1 (en) 2002-04-30
EP0780390B1 (de) 2002-07-31
EE03474B1 (et) 2001-08-15
BR9605968A (pt) 1998-08-18
AU7421696A (en) 1997-06-19
SV1996000109A (es) 1997-10-23
JP4104687B2 (ja) 2008-06-18
CZ288657B6 (cs) 2001-08-15
CU22774A3 (es) 2002-07-24
KR970042550A (ko) 1997-07-24
DK0780390T3 (da) 2002-11-11
BG62258B1 (bg) 1999-06-30
ZA9610405B (en) 1997-06-23

Similar Documents

Publication Publication Date Title
YU65096A (sh) Nova kristalna modifikacija cdch, postupak za njeno pripremanje i farmaceutski preparati koji je sadrže
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
NO995006L (no) Nye forbindelser
YU40701A (sh) Piperidini kao modulatori ccr5
EE200000318A (et) Uudsed ühendid
ATE216590T1 (de) Arzneimittelformulierungen für il-12
PT83647A (en) Process for the preparation of novel pharmaceutical benzimidazole derivatives and of pharmaceutical compositions containing the same
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
AU1446388A (en) Preparation of serine-n, n-diacetic acid and derivatives as complexing agents and detergents containing same
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2144054T3 (es) Complejos de tri(platino).
JPS6438086A (en) Mevalonic acid derivative and manufacture
NZ227990A (en) Cephemcarboxylic acid esters; pharmaceutical compositions and processes for preparation
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
EP0333000A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
WO2002034203A3 (en) Novel derivatives of phenyl 4-aminosalicylate and method of making the same
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
EP0332999A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
IT1254471B (it) Derivati ammidici della (r)-glicerofosforil-(s)-serina o del suo diacil derivato, un processo per la loro preparazione e relative composizioni farmaceutiche per il potenziamento dei processi di apprendimento
SE9704835D0 (sv) New compound
IT8120177A0 (it) Derivato della l-prolina, processo per la sua preparazione e composizioni terapeutiche che lo comprendono come principio attivo.